Boehringer settles Pradaxa suits

Share this article:

Boehringer Ingelheim is settling around 4,000 Pradaxa lawsuits for $650 million. The company announced Wednesday that it had reached a “comprehensive settlement of state and federal cases” and that the decision “enables Boehringer Ingelheim to focus solely on its mission of improving patients' lives.”

Bloomberg reports this breaks down to around $162,500 per suit and that the agreement comes just months before the first of several lawsuits were expected to begin in September.

The lawsuits center around claims that there was no antidote to prevent bleeding-related deaths among those who took the blood thinner.

BI announced earlier this month that it was going to start testing the antidote idarucizumab among Pradaxa patients.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.